SCHEMBL7708210

SCHEMBL7708210

CC1Oc2ccc(C(Cc3ccc(Cl)cc3Cl)NC(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 3/20 0.41
HSD17B10 Q99714 2/20 0.40
KDR P35968 1/20 0.38
IDO1 P14902 3/20 0.37
PARP1 P09874 3/20 0.37
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 2/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SMYD3 Q9H7B4 1/20 0.35
GLA P06280 1/20 0.35
MAPT P10636 1/20 0.35
XBP1 P17861 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7093383 0.91 MC4R (0.41) MC4RSMN1; SMN2TP53HSD17B10IDO1
SCHEMBL7708055 0.91 PARP1 (0.41) MC4RHSD17B10KDRIDO1PARP1
SCHEMBL7713338 0.89 PARP1 (0.42) SMN1; SMN2TP53HSD17B10KDRIDO1
SCHEMBL7711137 0.86 CTSL (0.45) SMN1; SMN2TP53HSD17B10KDRIDO1
SCHEMBL7713423 0.85 PARP1 (0.41) SMN1; SMN2TP53HSD17B10KDRIDO1
SCHEMBL7708086 0.84 CTSS (0.43) IDO1PARP1ALDH1A1KDM4ESMYD3
SCHEMBL7713374 0.83 PARP1 (0.50) SMN1; SMN2TP53HSD17B10IDO1PARP1
SCHEMBL7710779 0.83 TP53 (0.40) TP53HSD17B10KDRIDO1PARP1
SCHEMBL7704807 0.83 HSD17B10 (0.42) HSD17B10KDRIDO1PARP1HPGD
SCHEMBL7713294 0.82 PARP1 (0.42) SMN1; SMN2TP53IDO1PARP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed